Table 2.

Detected APC, KRAS, and BRAF Mutations in Serrated Polyps (HPs, SSAs, TSAs, and Mixed Polyps) and Adenomas (ADs) of Patients with HPS Compared with a Control Group

	Patients with HPS, No. (%)		Control group, No. (%)
Somatic mutation	Serrated polyps (n = 64)	AD (n = 20)	Serrated polyps (n = 42)	AD (n = 17)	P value
APC	0	9 (45)	0	7 (41)	NS
BRAF	48 (75)	0	20 (48)	0	0.007⁎
KRAS	4 (6)	0	7 (17)	4 (24)	0.029†

NS, not significant.

^⁎Statistically significant P value for BRAF mutation frequency in serrated polyps of patients with HPS compared with the frequency in serrated polyps of the control group.

^†Statistically significant P value for KRAS mutation frequency in ADs of patients with HPS compared with the frequency in ADs of the control group.